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It is generally accepted that the development of novel therapies to treat pregnancy-related
disorders, such as preeclampsia, is hampered by the paucity of research funding. Hence,
it is with great interest to become aware of at least three novel therapeutic approaches for
the treatment of this disorder: exploiting either the anticoagulant activity of antithrombin,
the free radical scavenging activity of alpha-1-microglobulin, or the regenerative capacity of
placenta-derived mesenchymal stem cells. As these projects are being carried out by small
biotech enterprises, the question arises of how they are able to fund such undertakings. A
novel strategy adopted by two of these companies is that they successfully petitioned US
and EU agencies in order that preeclampsia is accepted in the register of rare or orphan
diseases. This provides a number of benefits including market exclusivity, assistance with
clinical trials, and dedicated funding schemes. Other strategies to supplement meager
research funds, especially to test novel approaches, could be crowdfunding, a venture
that relies on intimate interaction with advocacy groups. In other words, preeclampsia
meets Facebook. Perhaps similar strategies can be adopted to examine novel therapies
targeting either the imbalance in pro- or anti-angiogenic growth factors, complement acti-
vation, reduced levels of placenta protein 13, or excessive neutrophil activation evident in
preeclampsia.
Keywords: orphan disease, crowdfunding, advocacy groups, social networking, antithrombin, alpha-1-
microglobulin, placental mesenchymal stem cells
INTRODUCTION
Obstetrical concerns such as preterm labor (PTL), intra-uterine
fetal growth restriction (IUGR), or preeclampsia (PE) remain huge
concerns with regard to maternal or fetal morbidity or mortality
(1–3). Indeed, prematurity has recently been listed as the leading
cause of child death world-wide, accounting for almost 1 million
of the 6.3 million children who die before the age of 5 (4, 5).
Although there has been considerable improvement in Western
Europe, Canada, and the US to reduce maternal mortality asso-
ciated with preeclampsia, it still accounts for one of the leading
causes of maternal mortality during pregnancy (3). In developing
countries, these rates are significantly higher, especially in cases
with severe early onset PE (6) or due to the progression to “full-
blown” eclampsia, where mortality rates can be as high as 15% (3).
All in all it is a sad reflection on global health care that almost 800
women die daily as a result of pregnancy-associated complications
(7), and it begs the question why efficacious intervention is so slow
in forthcoming or implementation (8).
Abbreviations: A1M, alpha-1-microglobulin; COMP, Committee for Orphan Med-
icinal Products; EMA, European Medicines Agency; FDA, Food and Drug Adminis-
tration; IND, investigational new drug; IUGR, intra-uterine fetal growth restriction;
ODA, Orphan Drug Act; NORD, National Organization for Rare Disorders; PE,
preeclampsia; PIFG, placenta growth factor; PLX, mesenchymal-like stem cells from
the placenta; PP13, placental protein 13; PTL, preterm labor; rAT, recombinant
antithrombin; sFlt-1, soluble fms-like tyrosine kinase-1; VEGF, vascular endothelial
growth factor.
WHY THE PROGRESS IN THE DEVELOPMENT OF
THERAPEUTICS IN FETO-MATERNAL MEDICINE SO SLOW?
Although the health care burden by pregnancy-related conditions,
specifically PE, is considerable with an estimated global health
care cost of $3 billion, it is dwarfed by the incidence of cancer,
which is approximately 28 times greater (8.2 million deaths per
annum) (9). A further concern that could hinder the active partic-
ipation of pharmaceutical industries in the development of new
drugs for prenatal use is the disaster experienced with thalidomide,
due to its unexpected teratogenic effect (10). It is of interest that
the underlying mechanism has only recently elucidated in 2014,
several decades later (11). A further issue is that the relationship
between patient and physician in the Internet age is complicated
by the reliance of the former on untrustworthy data or unfounded
skepticism of new untried developments (12, 13).
Consequently, the argument by pharmaceutical companies, or
diverse research funding agencies to focus their resources on more
pressing concerns, may at first hand appear rational. However,
closer scrutiny indicates that global R&D funding for pregnancy-
associated complications is grossly underfunded, either by the
private sector or national bodies, with less than 1% or the health
research budget in the US or UK being allocated to the topic of
reproductive health (14, 15). This indicates that pressing obstetri-
cal concerns such as PE have been related to the status of “orphan
diseases” or less, and consequently is listed as such by the Food and
Drag Administration (FDA) and European Commission (16).
www.frontiersin.org February 2015 | Volume 2 | Article 7 | 1
Hahn Advanced biological therapies for preeclampsia
Such scientific relegation has, however, led to an almost com-
plete stifling of the development of new therapeutic agents for
use in pregnancy, with the result that physicians are increasingly
obliged to resort to “off-label” use of drugs for which no safety
indication is available (17–19).
DOES BEING LABELED AN ORPHAN DISEASE HAVE ANY
BENEFITS?
It is unclear why PE could be listed as an “orphan or rare disease”
as the defining criteria for such status is an incidence of less than
5 in 10,000 individuals, granted that PE affects between 3 and 8%
of all pregnancies (20). In the context of the entire population,
however, the number of people affected by PE is quite small, and
has been estimated to be of the order of 3.8 per 10,000, thereby
comfortably securing a slot in the rare disease catalog (16).
A driving force behind the US Orphan Drug Act (ODA)
of 1983 and similar European, Japanese, Australian, or Singa-
porean regulations was the decision that “patients suffering from
rare conditions should be entitled to the same quality of treat-
ment as other patients” (21). The main aim of such legislation
is to provide specific incentives to promote drug development
for rare conditions. These include market exclusivity, reduction
in regulatory fees or subsidies (tax breaks) with clinical tri-
als (21). In addition, special funding schemes have been devel-
oped by the NIH (Office of Rare Diseases Research), the EU,
and other institutions (NORD: National Organization for Rare
Disorders), specifically targeting rare conditions (22). Successful
funding, however, may require lobbying or engagement by advo-
cacy groups (23). Consequently, successful funding may in future
require considerable political action and mobilization of interest
groups.
IS CROWDFUNDING THE SOLUTION?
If scientific success in future may depend on a meaningful inter-
action with advocacy groups, it appears obvious that this scenario
may be exploited to secure necessary financial resources by means
of crowdfunding. A development of social media and globally
linked communities, crowdfunding, is a method of raising venture
funds from a large number of individuals via the Internet (24–28).
To date most crowdfunding approaches have been used in the
arts or technology development, but scientific usage is increasing
rapidly.
An examination of 159 crowdfunding attempts using the #Sci-
fund platform indicated that success largely depended on the
degree of interaction between scientists and their audience, and
the ability to expand this network effectively (24). Although the
turn-over generated by the international crowdfunding industry
is proposed to be greater than $1 billion, with more than $200 mil-
lion being raised via a single website, the rewards for the scientific
community have been less spectacular, with the average amount
secured estimated to be less than $50,000 (24, 26, 27).
Nevertheless, crowdfunding may play an important role in
assisting the establishment of academic spin-off biotech compa-
nies geared toward the development of innovative therapies (25).
The incentive for crowdfunding participants in this instance is
the feature of equity and the possibility of a very high rate of
return.
ARE ANY INNOVATIVE BIOLOGICAL THERAPIES BEING
DEVELOPED?
In view of the largely negative preamble in this mini-review, it is
gratifying to note that at least three innovative biological thera-
peutic strategies are being pursued for the treatment of PE. It is
also noteworthy that all three are being carried out by small newly
established companies, solidifying the suspicion that PE does is
not an interesting feature for large pharmaceutical companies.
The first of these small companies is Revo Biologics Inc.,
which is investigating the use of recombinant antithrombin (rAT),
termed ATryn®, as an Investigational New Drug (IND) for the
treatment of preeclampsia in pregnant women. Their goal is not a
full cure but rather to prolong gestation, thereby decreasing fetal
or neonatal morbidity or mortality (29).
The rationale behind the approach of Revo Biologics Inc., is
that preeclampsia is associated with a pro-thrombotic condition
(30), and that previous use of anti-coagulants, such as antithrom-
bin, has been shown to have some benefit (29, 30). This includes at
least two prospective case-control or feasibility studies conducted
in Italy and Japan (31–33).
Enrollment to test ATryn® is underway in a Phase 3 clinical
trial termed Preserve-1 (Prospective Randomized Evaluation of
the Safety and Efficacy of Recombinant Antithrombin in Very
Preterm Preeclampsia) (29).
A second approach is being explored by A1M Pharma AB in
Sweden, a biotech spin-off from Lund University, which focuses
on the finding by the founders that alpha-1-microglobulin (A1M)
can act as a scavenger and remove toxic free radicles (34). By the use
of a sheep model for PE, which is induced by starvation-mediated
hemolysis, it was shown that exogenous A1M application lead to
significant amelioration, detected by an examination of placental
and kidney pathology (35). It is unclear if any clinical trials have
been launched or are planned to test A1M application in human
patients. Of interest is that A1M Pharma successfully lobbied the
European Medicines Agency (EMA) Committee for Orphan Med-
icinal Products (COMP) in order to secure an Orphan Drug status
for preeclampsia.
A third very intriguing development is that pursued by the
Israeli company Pluristem Therapeutics Inc., which has a series
of proprietary technologies focused on the isolation and expan-
sion of mesenchymal-like stem cells from the placenta (PLX) (36).
The use of these PLX cells has been explored for the treatment of
ischemia or to improve the engraftment of cord blood hemopoietic
stem cells (37–39). It now appears that Pluristem is considering
the use of these PLX cells for the treatment of preeclampsia, and is
following a similar strategy to that of A1M Pharma, in that it has
submitted a FDA Orphan Drug application for PE (40).
COULD OTHER STRATEGIES BE EXPLORED FOR THE
DEVELOPMENT OF NOVEL BIOLOGICAL THERAPIES?
The past decade has seen a huge expansion in our knowledge
of the underlying etiology involved the development of PE (41).
These include the discovery of an imbalance in the pro-angiogenic
cytokine PIGF (Placenta Growth Factor) and the anti-angiogenic
factor sFlt-1 (soluble fms-like tyrosine kinase 1) in cases at-risk
for PE, and the examination of how this anomaly to contributes
to endothelial dysfunction (42). Additional discoveries include
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the contribution of complement dysregulation to placental dam-
age (43), the possible involvement of placental galectins such as
PP13 (placental protein 13) in placental development and immune
modulation (44), or the excessive occurrence of neutrophil
extracellular traps (NETs) in preeclamptic placentae (45).
Of these the elevated presence of the anti-angiogenic factors
sFlt-1 would seem to be a prime target, as it has previously been
shown that extracorporeal removal of this factor by apheresis can
extend the pregnancy of women with manifest early onset PE by
as much as 23 days (46). An alternative may be to target com-
plement dysregulation, since treatment with a specific inhibitor
(eculizumab) has been shown to significantly prolong gestation
in a case with PE/HELLP syndrome, thereby improving neonatal
outcome (47).
Treatment with recombinant PP13 may be an attractive option
in future, granted that its application in pregnant rats is sug-
gested to reduce blood pressure (44). The involvement of excessive
NETosis in the etiology of auto-inflammatory conditions such as
rheumatoid arthritis (48, 49) or systemic lupus erythematosus
(SLE) (50, 51) opens up the possibility that novel therapeutics
will be developed to counter this undesired neutrophil activity
(52). This could pave the way for possible use in PE.
WHAT IS THE WAY FORWARD?
The low level of funding in reproductive medicine is a chal-
lenge, which need to be overcome if effective therapies are to be
developed for the numerous concerns which continue to beset
obstetrical practice. On the one hand this may rely on innova-
tive strategies such as crowdfunding or to somewhat subversive
methods, such as applying for orphan disease status. The success
of either will depend largely on adequate lobbying, which implies
that much closer ties with advocacy groups using social networks
will become the order of the day.
CONCLUDING REMARKS
In this review the focus was on three small companies who are
driving the development of new therapeutic strategies for the treat-
ment of PE, which makes it clear that innovation does not rely
on huge funding bodies or multinational pharmaceutical compa-
nies. Rather, like David when facing Goliath, it relies on flexibility,
nimbleness of feet, and a vision or calling to make a significant
contribution to the betterment of humankind.
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